Amgen is voluntarily recalling hundreds of thousands of Corlanor and Sensipar bottles after unexpected foreign material was found on tablet surfaces. Regulators say patient risk is low but recommend checking labels and consulting your pharmacist.

A Portland seven‑time skin‑cancer survivor helped push a law that paves a path for Medicare to cover multi‑cancer blood tests — implementation depends on FDA and CMS reviews.

The FDA told Amazon it sold three unapproved topical products marketed for penile conditions and gave the company 15 business days to respond.

A National Academies review found ABA meets the evidence bar, but TRICARE’s demonstration rules and paperwork are keeping many military families from hands‑on care.

A watchdog says crisis pregnancy centers are advertising they can "rule out" ectopic pregnancy after a single scan. Medical groups say diagnosis usually requires follow‑up testing.

A UNSW‑led review published in Carcinogenesis finds e‑cigarettes "likely" carcinogenic; U.S. health agencies and experts are weighing the evidence.

A Pittsburgh verdict has thrust the unregulated delta‑8 THC market into the spotlight as health officials warn of contaminants and adverse reactions.

Listening to Mothers IV finds Medicaid-covered birthing people report delayed prenatal care, higher complication rates, and widespread feelings of being ignored.

The FDA says Inventia-made chlorthalidone 25 mg failed dissolution testing; two lots — 11,460 bottles — were recalled nationwide. Patients should consult their pharmacist before changing therapy.

A Psychological Bulletin review of 307 studies finds rising perfectionism among college students, with sharp increases in worry over mistakes and socially prescribed pressure.

Starting July 1, 2026, Medicare’s GLP‑1 Bridge will let select Part D enrollees get Wegovy, Zepbound or Foundayo for $50 a month — but strict BMI and health rules apply.

A University of Georgia meta‑analysis found tirzepatide produced the largest weight loss among GLP‑1 therapies in non‑diabetic adults, but questions remain on durability and access.

UNLV researchers were among co‑authors of a GBD study published in Med that finds the U.S. had the highest substance use disorder prevalence in 2023 and projects increases to 2050 without intervention.